AR-001, our lead product candidate is a best-in-class dry powder formulation of niclosamide optimized for self delivery using a capsule-based dry powder inhalation device. This proprietary drug-device combination product benefits from the established safety on niclosamide and the optimal target coverage that will be achieved by direct delivery to the airways. AR-001 is currently being tested in IND enabling in vivo studies to establish safety and determine optimal clinical dose ranges.
In addition to our primary indications of severe asthma and COPD, AR-001 holds promise to treat other diseases that involve pathologic calcium signaling in the airways. These Tier 2 indications are highlighted below and the company will seek opportunities to generate supporting preclinical data as appropriate.